

CLIA #: 31D2026917

PATIENT DEMOGRAPHICS

PATIENT INFORMATION:	PHYSICIAN INFORMATION:	SPECIMEN INFORMATION:
Patient, Test DOB: 1/1/1960 Gender/Age: M/66	Test Physician, MD Test Practice 300 Columbus Circle Suite A, Edison, NJ 08837 (866) 909-7284, Fax:(908) 272-1478	ACCESSION #: TS26-0025X PROCEDURE DATE: 4/19/2026 DATE RECEIVED: 4/20/2026 REPORTED ON: 4/20/2026

CLINICAL HISTORY: Hematuria.

SPECIMEN RECEIVED: Voided urine, 90 cc of yellow clear fluid, in PreservCyt™

URINE CYTOLOGY DIAGNOSIS

SPECIMEN: SATISFACTORY FOR EVALUATION.

DIAGNOSIS: ATYPICAL, CANNOT RULE OUT UROTHELIAL CELL NEOPLASIA.

MICROSCOPIC FINDINGS:


- Scattered urothelial cells, some with mild atypia.
- Squamous cells.
- Neutrophils.
- Erythrocytes.

COMMENTS:

- Suggest clinical correlation and follow up as appropriate.

- **POSITIVE URO17 - HIGH**

EXPRESSION: (Number of positive cells: ≥ 20) The probability of Urothelial cancer is elevated. Additional testing and diagnostic workup are recommended. URO17 results should be utilized in conjunction with urine cytology results and other known clinical risk factors to further stratify overall risk of Urothelial cancer.



UROVYSION™ FISH ANALYSIS

DIAGNOSIS: POSITIVE *

INTERPRETATION: POSITIVE FOR ANEUPLOIDY CEP GAIN OF 3, 7, 17.

Total Urothelial Cells Scored: 31	
Marker	Interpretation
CEP3	Suspicious
CEP7	Suspicious
CEP17	Suspicious
LSI 9p21	Negative

SUMMARY: A total of 31 cells analyzed, 6 cells showed a gain of 2 or more chromosomes (3,7,17).

***POSITIVE BY ANEUPLOIDY :** ≥ 4 cells with 3 or more signals of 2 or more CEP (3,7 or 17).

Pap stain performed.

A negative urine cytology test does not rule out urothelial carcinoma. This test has a low sensitivity (50%) in detecting low-grade urothelial carcinoma. Am. J. Clin. Pathol. 2009; 132:785-793.

UroVysion™ Testing: The performance of the Urovysion™ Assay (Abbott Molecular, Chicago, IL) for detection of urinary tract cancers has been approved by the Food and Drug Administration and is intended for use as a screen for genetic abnormalities in urothelial cells. This test is designed to detect aneuploidy for chromosomes 3,7,17 and homozygous deletion of the 9p21 locus via FISH. The Urovysion™ FISH assay test has not been approved for the utilization of bladder washings or upper urinary tract specimen. When utilized for these, the results should be interpreted in correlation with clinical history. The Urovysion™ assay was designed to detect genetic changes associated with most bladder cancers, there will be some bladder cancers whose genetic changes cannot be detected by the Urovysion™ assay. **Negative result does not rule out urothelial carcinoma.**